Nalbuphine ER: Phase I data

An open-label Phase I trial in 14 end-stage renal disease (ESRD) patients with uremic pruritus who were receiving hemodialysis showed that twice-daily oral Nalbuphine ER escalated every 3 days from 30 mg to 240 mg over 17 days dose-dependently reduced itching in 13 patients, with a mean reduction in VAS score for itching from baseline of 0.9 points for the 30 mg dose and 2.8 points for the 240 mg dose. Nalbuphine ER was well tolerated. Data were presented at the Society for Investigative Dermatology meeting in Albuquerque. ...